According to the latest market report published by Future Market Insights, titled ‘Global Amniotic Membrane Market: Global Industry Analysis 2013 – 2017 and Opportunity Assessment 2018 – 2028′, the global amniotic membrane market is expected to expand at a CAGR of 9.3% over the forecast period 2018-2028.FMI estimate.
TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain
Investigators will evaluate the dosage and safety of Cryopreserved Amniotic Membrane and Cryopreserved Umbilical Cord TTAX03 for pain relief and functional improvement of facet joint osteoarthritis in the lumbosacral region
News provided by
Share this article
Share this article
MIAMI, March 8, 2021 /PRNewswire/ Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from Osteoarthritis (OA). This Phase 1 randomized, double-blinded, placebo-controlled, dose-finding study will include a one-year follow-up to assess TT
Share this article
CENTENNIAL, Colo., Feb. 23, 2021 /PRNewswire/
AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products, today announced the first patients have been enrolled in its clinical study titled,
A Randomized, Controlled Study to
Evaluate Effectiveness of AlloWrap® Amniotic Membrane for the Reduction of Post-Operative Soft Tissue Inflammation in Two-Level Anterior Cervical Discectomy and Fusion (ACDF) Procedures.
There are an estimated 300,000 ACDF procedures performed annually in the United States. Despite the overall positive outcomes of these procedures, one potentially costly and painful complication is inflammation of the surrounding tissue, which can cause painful swallowing and/or loss of language. The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.